Inion Oyj - Company Announcement

Inion plans further cost reductions

Inion Oy
(“Inion or the “Company”)

Inion plans further cost reductions
  
Tampere, Finland and Guildford, UK. 19 March 2009, Inion (LSE: IIN.L), a
company focused on the development and commercialisation of novel biodegradable
medical implants, today announces that it is implementing further cost
reduction measures while it continues to seek additional funding to support its
strategy. The measures, which were negotiated at the time of the cooperation
talks with employees and were finalised in January 2009, will result in the
suspension of 33 employees in Finland. The measure is regarded under Finnish
law as being made until further notice and so employment contracts of those
affected will be suspended following a notice period of one month, after which
there will be no further cost to Inion until such time as the Company has
raised sufficient working capital for them to be reinstated. The cost savings
to the Company are expected to be approximately €200,000 per month. Following
this action, Inion will have 29 active employees. 

Chris Lee, Inion's CEO, said, “We are facing extremely challenging financial
market conditions, which have unfortunately resulted in the measures we have
taken today to conserve our cash resources. We remain fully committed to
securing the funding needed to ensure the future of the Company so that we can
realise the significant potential we see in our novel spine product offering,
which continues to generate growing sales in key markets.” 

The Company will continue to keep the market updated, as appropriate.

- Ends -

For further information, please contact:

Inion Oy 
Chris Lee, Chief Executive Officer
Julien Cotta, Chief Financial Officer
Tel: +44 (0)1483 685390

Citigate Dewe Rogerson
Mark Swallow / David Dible	
Tel: +44 (0)207 638 9571


About Inion (www.inion.com)
Inion Oy is a medical devices company focused on the development and successful
commercialisation of innovative and unique biodegradable and bioactive surgical
implants in selected high value orthopaedic market segments. 

Inion's core expertise and technology lies in the design and manufacture of
innovative biodegradable plates, screws, pins and membranes, which are used to
enhance the healing of bone or soft tissue injuries to the skeleton, such as
those caused by trauma or by reconstructive surgery. Inion implants are made
from its proprietary Inion Optima™ family of biomaterials, with properties
tailored for specific surgical applications, in terms of strength, flexibility
and rate of degradation 
 
Inion is also focused on developing proprietary new bioactive and biodegradable
biomaterials that promote bone healing and accelerate patient rehabilitation. 

Inion was incorporated in early 2000 and listed on the Official List of the UK
Listing Authority in December 2004 (ticker: IIN). The Company has offices in
the UK and USA, and its head office, R&D and production facilities are in
Tampere, Finland. 

This announcement includes "forward-looking statements" which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Group's products), and any statements
preceded by, followed by or that include forward-looking terminology such as
the words "targets", "believes", "estimates", "expects", "aims", "intends",
"will", "can", "may", "anticipates", "would", "should", "could" or similar
expressions or the negative thereof. Such forward-looking statements involve
known and unknown risks, uncertainties and other important factors beyond the
Group's control that could cause the actual results, performance or
achievements of the Group to be materially different from future results,
performance or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous assumptions
regarding the Group's present and future business strategies and the
environment in which the Group will operate in the future. Among the important
factors that could cause the Group's actual results, performance or
achievements to differ materially from those in forward-looking statements
include those relating to Inion's funding requirements, regulatory approvals,
reliance on third parties, intellectual property, key personnel and other
factors. These forward-looking statements speak only as at the date of this
announcement. The Group expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking statements
contained in this announcement to reflect any change in the Group's
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statements are based. As a result of these
factors, prospective investors are cautioned not to rely on any forward-looking
statement.